Back to Journals » ClinicoEconomics and Outcomes Research » Volume 10

Societal costs due to meningococcal disease: a national registry-based study

Authors Gustafsson N, Stallknecht SE, Skovdal M, Poulsen PB, Østergaard L

Received 30 May 2018

Accepted for publication 27 August 2018

Published 2 October 2018 Volume 2018:10 Pages 563—572

DOI https://doi.org/10.2147/CEOR.S175835

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Ms Justinn Cochran

Peer reviewer comments 3

Editor who approved publication: Professor Samer Hamidi


Nina Gustafsson,1 Sandra Elkjær Stallknecht,1 Mette Skovdal,2 Peter Bo Poulsen,3 Lars Østergaard4

1Incentive, Holte, Denmark; 2Vaccines, Pfizer Denmark, Ballerup, Denmark; 3Health and Value, Pfizer Denmark, Ballerup, Denmark; 4Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark

Purpose: Limited detailed evidence exists on the societal costs of meningococcal disease. The objective of this study was to estimate the average 5-year societal cost of events attributable to meningococcal disease in Denmark.
Methods: The study was based on the nationwide Danish registries. Incident patients diagnosed with meningococcal disease were identified and each matched with two controls, using direct matching on age, gender, and level of education. Siblings constituted a secondary control population where one patient was matched with one sibling control without meningococcal disease. Costs related to health care in the primary and secondary sectors, prescription medicine, municipality home care services and costs of production loss, ie, estimated loss of yearly earnings, were included (1997–2015).
Results: The incidence of meningococcal disease fluctuated between 1980 and 2015. The average attributable societal costs were highest the first year after diagnosis, with costs equaling USD 18,920 per event in the primary study population (matched controls) and USD 16,169 in the secondary study population (sibling controls). Hospital admission costs accounted for 65% and production loss for 30%; however, having a lifetime perspective and including loss due to premature death further increase the costs of meningococcal disease events.
Conclusion: The costs of meningococcal disease are substantial, and the estimated costs of event may be informative in evaluating the impact of preventive interventions targeting meningococcal disease.

Keywords: meningitis, sepsis, national registries, health care, hospitalization, attributable costs of events

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]